...
search icon
nuvl-img

Nuvalent Inc, Common Stock

NUVL

NSQ

$82.39

+$2.13

(2.65%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.85B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
326.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.38
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$61.8 L
$113.51 H
$82.39

About Nuvalent Inc, Common Stock

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNUVLSectorS&P500
1-Week Return1.78%0.54%0.54%
1-Month Return5.25%3.28%1.66%
3-Month Return-9.63%3.01%3.83%
6-Month Return7.98%-4.69%9.77%
1-Year Return0.49%1.41%23.47%
3-Year Return401.16%15.72%42.73%
5-Year Return339.41%42.38%82.01%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses10.36M16.91M45.82M86.11M149.49M[{"date":"2019-12-31","value":6.93,"profit":true},{"date":"2020-12-31","value":11.31,"profit":true},{"date":"2021-12-31","value":30.65,"profit":true},{"date":"2022-12-31","value":57.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(10.36M)(16.91M)(45.82M)(86.11M)(149.49M)[{"date":"2019-12-31","value":-1035800000,"profit":false},{"date":"2020-12-31","value":-1690500000,"profit":false},{"date":"2021-12-31","value":-4581700000,"profit":false},{"date":"2022-12-31","value":-8610800000,"profit":false},{"date":"2023-12-31","value":-14949200000,"profit":false}]
Total Non-Operating Income/Expense---8.51M46.55M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":18.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(11.81M)(14.56M)(46.34M)(81.85M)(126.22M)[{"date":"2019-12-31","value":-1180900000,"profit":false},{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-8185400000,"profit":false},{"date":"2023-12-31","value":-12621900000,"profit":false}]
Income Taxes1.45M(2.35M)521.00K(8.51M)(167.90K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-161.89,"profit":false},{"date":"2021-12-31","value":35.91,"profit":true},{"date":"2022-12-31","value":-586.35,"profit":false},{"date":"2023-12-31","value":-11.57,"profit":false}]
Income After Taxes---(73.35M)(126.05M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-7334600000,"profit":false},{"date":"2023-12-31","value":-12605110500,"profit":false}]
Income From Continuous Operations(11.81M)(14.56M)(46.34M)(81.85M)(114.05M)[{"date":"2019-12-31","value":-1180900000,"profit":false},{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-8185400000,"profit":false},{"date":"2023-12-31","value":-11405000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(11.81M)(14.56M)(46.34M)(73.35M)(126.22M)[{"date":"2019-12-31","value":-1180900000,"profit":false},{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-7334600000,"profit":false},{"date":"2023-12-31","value":-12621900000,"profit":false}]
EPS (Diluted)0.34(2.39)(4.33)(1.64)(2.16)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-695.22,"profit":false},{"date":"2021-12-31","value":-1260.92,"profit":false},{"date":"2022-12-31","value":-477.58,"profit":false},{"date":"2023-12-31","value":-629,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NUVL
Cash Ratio 22.85
Current Ratio 23.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NUVL
ROA (LTM) -18.63%
ROE (LTM) -29.57%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NUVL
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NUVL
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 5.09
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Nuvalent Inc share price today?

Nuvalent Inc (NUVL) share price today is $82.39

Can Indians buy Nuvalent Inc shares?

Yes, Indians can buy shares of Nuvalent Inc (NUVL) on Vested. To buy Nuvalent Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NUVL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nuvalent Inc be purchased?

Yes, you can purchase fractional shares of Nuvalent Inc (NUVL) via the Vested app. You can start investing in Nuvalent Inc (NUVL) with a minimum investment of $1.

How to invest in Nuvalent Inc shares from India?

You can invest in shares of Nuvalent Inc (NUVL) via Vested in three simple steps:

  • Click on Sign Up or Invest in NUVL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nuvalent Inc shares
What is Nuvalent Inc 52-week high and low stock price?

The 52-week high price of Nuvalent Inc (NUVL) is $113.51. The 52-week low price of Nuvalent Inc (NUVL) is $61.8.

What is Nuvalent Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nuvalent Inc (NUVL) is 5.09

What is the Market Cap of Nuvalent Inc?

The market capitalization of Nuvalent Inc (NUVL) is $5.85B

What is Nuvalent Inc’s stock symbol?

The stock symbol (or ticker) of Nuvalent Inc is NUVL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top